|Day Low/High||48.47 / 49.88|
|52 Wk Low/High||44.30 / 70.05|
A split Congress is the best-case scenario for the drug industry, several analysts said.
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Credit Suisse Annual Health Care Conference on Wednesday, November 14, 2018 in Scottsdale, AZ.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S.
-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H'19 --
Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial...
Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
The Dow Jones Industrial Average snaps back solidly Thursday after plunging more than 600 points in the previous session.
Bristol-Myers Squibb posts stronger-than-expected third-quarter earnings Thursday and boosts its full-year profit outlook.
Global stocks were awash with red in overnight trading Thursday, loping billions in value from equity markets around Asia following last night's late-trading collapse on Wall Street which has erased year-to-date gains for benchmarks around the world amid concerns over weakening U.S. earnings growth, rising geo-political tensions and the unknown outcome of trade disputes between Washington and its major economic partners.
It becomes difficult for me to tell you where to run in these markets...
SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2018 which were highlighted by strong sales and operating performance along with key regulatory and clinical milestones across the portfolio.
There is clear divergence between the best and the worst performers in each sector this earnings season.
Shares of Mirati Therapeutics fell Monday after the drug developer released a progress report of an early stage clinical trial of its lung cancer drug used in conjunction with a Bristol-Myers Squibb Co. medication.
Bristol-Myers Squibb fall sharply after the U.S. Food & Drug Administration extends the approval date for a combination-drug treatment for lung cancer patients.
Stocks are mixed after rising earlier in the session following a rally in China that saw stocks soar to their biggest single-day gain in nearly three years.
Bristol-Myers Squibb Company (NYSE:BMY) today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or...
Bristol-Myers Squibb Company (NYSE: BMY) today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of...
Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from a cohort of the CheckMate -142 study in which Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) demonstrated durable clinical benefit as a first-line treatment in patients with...
Bristol-Myers Squibb Company (NYSE: BMY) today announced follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in patients with platinum-pretreated metastatic urothelial carcinoma (mUC).
Bristol-Myers Squibb Company (NYSE:BMY) announced updates regarding regulatory actions by health authorities in the United States (U.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that 28 abstracts related to ORENCIA ® (abatacept) and the Company's immunoscience pipeline will be presented at the 2018 American College of Rheumatology and Association of Rheumatology Health...
Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung...
NEW YORK and HOLON, Israel, Oct. 11, 2018 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of...
Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in...
Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its incoming CEO to hear about her journey and how immunotherapies are taking the lead.
Diagnostic firms can have an advantage of recurring revenue streams.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the Company's type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone (EPd) for...
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.